Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis

Meizhen Xu, Yina Liu, Dan Li, Xuelin Wang, Shuang Liang, Gaochuan Zhang _ and Xiaoqin Yang

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:1248-1256. https://doi.org/10.18632/oncotarget.18981

Metrics: PDF 1254 views  |   HTML 2184 views  |   ?  


Meizhen Xu1,*, Yina Liu1,*, Dan Li2,3,6,*, Xuelin Wang4, Shuang Liang5, Gaochuan Zhang1 and Xiaoqin Yang1

1School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China

2Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China

3School of Life Science and Technology, Tongji University, Shanghai, China

4Yushan Town, Kunshan, China

5Scotch Plains, New Jersey, USA

6Present address: Jiayin BioTechnology Co., Ltd., Shanghai, China

*These authors contributed equally to this work

Correspondence to:

Gaochuan Zhang, email: [email protected]

Xiaoqin Yang, email: [email protected]

Keywords: ERCC5, polymorphism, cancer, meta-analysis, platinum-based chemotherapy

Received: November 23, 2016     Accepted: June 17, 2017     Published: July 04, 2017


It is suspected that ERCC5 rs1047768 and rs17655 polymorphisms influence the response to platinum-based chemotherapy. This meta-analysis was performed to summarize the scattered evidence regarding the association between these two polymorphisms and sensitivity to platinum-based treatment. Thirteen studies were included after a comprehensive literature search. The pooled odds ratios and 95% confidence intervals suggested that the C allele of the ERCC5 rs1047768 polymorphism is associated with elevated sensitivity to platinating agents, especially for Chinese patients. However, no difference among rs17655 genotypes could be detected.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18981